ValuEngine cut shares of Sanofi (NYSE:SNY) from a buy rating to a hold rating in a research note released on Friday morning.
Other equities analysts also recently issued reports about the company. Barclays raised Sanofi from an underweight rating to an equal weight rating in a research report on Wednesday, November 15th. Cowen set a $48.00 price objective on shares of Sanofi and gave the company a hold rating in a report on Monday, December 18th. UBS Group reissued a neutral rating on shares of Sanofi in a report on Monday, January 15th. JPMorgan Chase & Co. reissued a neutral rating on shares of Sanofi in a report on Thursday, January 11th. Finally, Nord/LB reissued a neutral rating on shares of Sanofi in a report on Tuesday, January 2nd. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and two have issued a buy rating to the company. The company currently has an average rating of Hold and a consensus target price of $51.50.
Sanofi (SNY) opened at $41.55 on Friday. The stock has a market capitalization of $108,420.00, a price-to-earnings ratio of 18.47, a PEG ratio of 2.36 and a beta of 0.85. The company has a current ratio of 1.59, a quick ratio of 1.16 and a debt-to-equity ratio of 0.26. Sanofi has a 12-month low of $40.18 and a 12-month high of $50.65.
Several institutional investors and hedge funds have recently made changes to their positions in SNY. Southpoint Capital Advisors LP purchased a new stake in shares of Sanofi during the second quarter valued at $57,492,000. BlackRock Inc. grew its holdings in shares of Sanofi by 47.6% during the second quarter. BlackRock Inc. now owns 2,235,422 shares of the company’s stock valued at $107,100,000 after buying an additional 720,523 shares during the last quarter. Boston Partners grew its holdings in shares of Sanofi by 6.2% during the third quarter. Boston Partners now owns 8,664,983 shares of the company’s stock valued at $431,429,000 after buying an additional 503,799 shares during the last quarter. Janus Henderson Group PLC purchased a new stake in shares of Sanofi during the second quarter valued at $22,558,000. Finally, Fisher Asset Management LLC grew its holdings in shares of Sanofi by 3.3% during the third quarter. Fisher Asset Management LLC now owns 14,082,257 shares of the company’s stock valued at $701,156,000 after buying an additional 443,799 shares during the last quarter. 9.09% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “ValuEngine Lowers Sanofi (SNY) to Hold” was originally published by Stock Observer and is the property of of Stock Observer. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.thestockobserver.com/2018/02/06/valuengine-lowers-sanofi-sny-to-hold.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.